News

The modification is based on the analysis of data from the recently completed Phase II clinical trial (MN-221-CL-006), which evaluated MN-221 at planned escalating doses in patients with

We are thrilled about our partnership with QIAGEN, as it pairs two companies to create an industry leading product, stated Steve Frisch, senior vice president, global engineering services.

Following the validation of MAA, the dossier is distributed to members of the Committee for Medicinal Products for Human Use (CHMP) for formal review to determine whether regadenoson

The open-label, dose-escalating study to evaluate the safety, tolerability and pharmacokinetics of the locally administered product in a total of 22 patients with primary or recurrent non-muscle invasive

This proposal represents Novartis’ only and final price revision to this offer, as May 28 is the last day on which the price can be revised. Earlier, Novartis

The company declared a gross profit of $67.8 million for fiscal 2009, compared to a gross profit of $84.7 million during fiscal 2008, a decrease of 20%. The

Earlier in July 2008, Bayer’s partner Johnson & Johnson filed for the approval to market Rivaroxaban. FDA has not requested any new clinical or non-clinical studies to be

Shimmer Research vice president Kieran Daly said, “We have 30 to 40% of our business in the US, and the majority of that is in the northeast corridor.

“The spectrum that has been provided should be adequate for the foreseeable future for implantable medical devices,” Knapp said. “However, new applications for medical technology that uses radio